Broadcom stock price ticks up as tariff jitters return and chip investors brace for earnings week

Broadcom stock price ticks up as tariff jitters return and chip investors brace for earnings week

February 23, 2026

New York, February 23, 2026, 10:59 (ET) — Regular session

Broadcom Inc. (AVGO) climbed roughly 0.4% to $333.83 by late morning Monday, with the stock bouncing from $328.18 to $338.39 earlier on. Shares kicked off the session at $332.51, and so far, volume is running near 4.2 million.

It’s a minor shift, but the timing stings. Chip stocks are still searching for solid ground, and Broadcom sits right at the crossroads—data-center spend, telecom capex, and enterprise software budgets all in play.

Broadcom’s shares are feeling the push and pull of both political headlines and heavyweight AI hardware players. After President Donald Trump rolled out a fresh 15% global tariff—this coming right after a Supreme Court decision on Friday that struck down most of his prior tariffs—U.S. stocks slid. “You simply can’t bet against Trump. He wants tariffs, and he’s going to find a way to implement them,” said Thomas Hayes, chairman at Great Hill Capital LLC. Nvidia, meanwhile, gained ground heading into its quarterly results on Wednesday, according to Reuters. Reuters

Broadcom investors are laser-focused: cloud clients’ appetite for AI infrastructure remains front and center, and there’s scrutiny on whether networking silicon keeps expanding as spending tightens. Miss the signals, and patience runs thin.

The software angle brings its own complexity. Broadcom’s infrastructure software business, centered on VMware, now binds the company closer to the spending cycles of corporate IT — where contract renewals and price points can matter just as much as moving chips out the door.

Broadcom rolled out its BroadPeak radio digital front-end SoC last week, pitching it for next-gen 5G Advanced and the early wave of 6G wireless equipment. The company says the chip is built for massive MIMO setups—those hefty antenna arrays that help networks handle more traffic—and can slash power consumption by as much as 40% compared to current options. “The BroadPeak SoC … [delivers] up to 40% greater efficiency for next-generation base stations,” said Vijay Janapaty, who heads Broadcom’s Physical Layer Products Division as vice president and general manager. GlobeNewswire

The upside here remains razor-thin—hardly a new story. Broadcom flagged back in December that its rising sales of lower-margin custom AI processors were putting pressure on its bottom line, a clear signal that heftier AI revenue doesn’t always boost margins. “Right now, the spending intentions still seem so big by so many, hitting that panic button is premature,” said Ben Reitzes, analyst at Melius Research. Reuters

Tariffs just pile on, particularly for hardware supply chains and those customers with heavy buying cycles. With policy details still fuzzy, traders usually react fast—then figure out the rest after.

AVGO traders are eyeing the company’s next earnings release—Broadcom will post its first-quarter fiscal 2026 numbers after the bell on March 4. The conference call kicks off at 5 p.m. ET.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • Novartis Wins UK High Court Case to Keep Entresto SPC, Stopping Accord Generic Bid
    August 14, 2026, 8:44 AM EDT. Novartis kept its UK Supplementary Protection Certificate for Entresto after a High Court ruling, which holds off Accord Healthcare from launching a generic until at least 2028. The SPC, set to run past the original patent's end in January 2023, covers valsartan and sacubitril in combination. Judge Richard Meade threw out Accord's challenge to the SPC after the exclusivity period lapses in November 2026, finding the SPC both valid and infringed. The result lines up with a similar Dutch court decision backing the SPC. Novartis used Bristows and Three New Square in the case.